Beauty Health (NASDAQ:SKIN – Get Free Report) and Co-Diagnostics (NASDAQ:CODX – Get Free Report) are both small-cap medical companies, but which is the better stock? We will contrast the two businesses based on the strength of their analyst recommendations, risk, earnings, profitability, valuation, dividends and institutional ownership.
Risk & Volatility
Beauty Health has a beta of 1.24, indicating that its stock price is 24% more volatile than the S&P 500. Comparatively, Co-Diagnostics has a beta of 1.42, indicating that its stock price is 42% more volatile than the S&P 500.
Institutional and Insider Ownership
93.3% of Beauty Health shares are held by institutional investors. Comparatively, 15.0% of Co-Diagnostics shares are held by institutional investors. 41.0% of Beauty Health shares are held by company insiders. Comparatively, 5.4% of Co-Diagnostics shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.
Analyst Ratings
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Beauty Health | 1 | 6 | 1 | 0 | 2.00 |
| Co-Diagnostics | 1 | 2 | 1 | 0 | 2.00 |
Beauty Health presently has a consensus price target of $2.42, indicating a potential upside of 196.57%. Co-Diagnostics has a consensus price target of $67.50, indicating a potential upside of 4,185.71%. Given Co-Diagnostics’ higher probable upside, analysts plainly believe Co-Diagnostics is more favorable than Beauty Health.
Profitability
This table compares Beauty Health and Co-Diagnostics’ net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| Beauty Health | -3.16% | -15.40% | -1.74% |
| Co-Diagnostics | -7,546.43% | -125.46% | -109.64% |
Earnings & Valuation
This table compares Beauty Health and Co-Diagnostics”s revenue, earnings per share and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| Beauty Health | $300.80 million | 0.35 | -$9.52 million | ($0.20) | -4.08 |
| Co-Diagnostics | $622,489.00 | 9.11 | -$46.90 million | ($29.73) | -0.05 |
Beauty Health has higher revenue and earnings than Co-Diagnostics. Beauty Health is trading at a lower price-to-earnings ratio than Co-Diagnostics, indicating that it is currently the more affordable of the two stocks.
Summary
Beauty Health beats Co-Diagnostics on 8 of the 12 factors compared between the two stocks.
About Beauty Health
The Beauty Health Company designs, develops, manufactures, markets, and sells aesthetic technologies and products worldwide. The company's flagship product includes HydraFacial that enhance the skin to cleanse, extract, and hydrate the skin with proprietary solutions and serums. Its products also comprise Syndeo, a Delivery System designs to connects providers to the consumer's preferences to create a more personalized experience; consumables, such as single-use tips, solutions, and serums used to provide a hydrafacial treatment; SkinStylus SteriLock Microsystem, a microneedling device used for the treatment of enhancing appearance of surgical or traumatic hypertrophic scars on the abdomen and facial acne scarring in Fitzpatrick skin types I, II, and III; and Keravive, a treatment for scalp health. The company was founded in 1997 and is headquartered in Long Beach, California.
About Co-Diagnostics
Co-Diagnostics, Inc., a molecular diagnostics company, develops, manufactures, and sells reagents used for diagnostic tests that function through the detection and/or analysis of nucleic acid molecules in the United States and internationally. The company offers Co-Dx PCR platform, a polymerase chain reaction (PCR) testing to patients in point-of-care and at-home setting. It also provides PCR diagnostic tests for COVID-19, influenza, tuberculosis, hepatitis B and C, human papillomavirus, malaria, chikungunya, dengue, and the zika virus. In addition, the company offers three multiplexed tests to test mosquitos for the identification of diseases carried by the mosquitos; molecular tools for detection of infectious diseases, liquid biopsy for cancer screening, and agricultural applications; tests that identify genetic traits in plant and animal genomes; and portable diagnostic device designed to bring PCR to patients in point-of-care and at-home settings. The company was incorporated in 2013 and is headquartered in Salt Lake City, Utah.
Receive News & Ratings for Beauty Health Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Beauty Health and related companies with MarketBeat.com's FREE daily email newsletter.
